5 things to know about Cerner's recent legal insider trading

  • Small
  • Medium
  • Large

Cerner's stock gained 0.64 (+0.94 percent) so far in 2018, according to Economics and Money.

The company's 52-week range is $47.09 to $73.86, and its 3-month range is $62.85 to $73.86.

However, a number of executives at the company engaged in insider trading activities within the past 12 months, which may offer insights into the stock's performance. These activities are legal insider trades, meaning corporate insiders — such as officers, directors and employees — are buying and selling stock in their own companies, according to the U.S. Securities and Exchange Commission.  

Here are five things to know.

1. In the last three months, Cerner had seven insider traders, all of which were sales and none of which were open market buys.  

2. The total number of shares traded in the last 90-day period is 648,000.

3. In the last year, there were 46 insider trades, including 11 open market buys and 35 sells, representing 27.03 million shares traded. A total of 12.03 million shares of CERN were purchased and 15 million shares were sold.

4. Becker's Hospital Review reported in December that Cliff Illig, interim CEO, chairman of the board and co-founder of Cerner, sold 530,000 shares of company stock from a revocable trust for $35 million. Mr. Illig still maintains 13.25 million shares of CERN.

5. Later in December, Becker's Hospital Review reported company President Zane Burke sold $3.5 million in stock, leaving him with 26,799 shares.

Editor's Note: This article was updated on Jan. 8, 2018 at 9:31 a.m. to clarify that the insider trades were legal. The headline has been updated to reflect "legal insider trading" as opposed to "insider trading," and a definition of legal insider trading has been added.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars